Core Points - AstraZeneca signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone Management Committee, announcing an additional investment of approximately $136 million to expand production capacity in Qingdao [1] - The Qingdao project will utilize energy-saving technologies to achieve near-zero carbon operations [1] Company Operations - AstraZeneca has three major production bases in China located in Wuxi, Taizhou, and Qingdao [1] - The Wuxi base has achieved 100% renewable energy usage and is the first in the industry to implement innovative clean heating solutions, receiving carbon neutrality certification [1] - The Taizhou base has reduced carbon emissions by 97.5% compared to 2015 [1] - The Qingdao base, currently under construction, is expected to achieve near-zero carbon operations upon commencement of production [1] Industry Engagement - This year marks AstraZeneca's eighth participation in the China International Import Expo (CIIE), showcasing innovative therapies across multiple disease areas [1] - Over the past seven years, AstraZeneca has introduced 18 "CIIE treasures," covering respiratory, renal, digestive, rare diseases, autoimmune diseases, and oncology, providing more treatment options for patients [1] - AstraZeneca's Global Executive Vice President and Head of International Business, Iskra Reic, emphasized the company's commitment to deepening engagement in China and contributing to the country's role as a global hub for healthcare innovation [1]

Core Insights - AstraZeneca showcased its commitment to expanding production in China at the 8th China International Import Expo, highlighting its latest achievements in sustainable development and innovative drug offerings [1][2] - The company signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone, committing to an additional investment of approximately $136 million to enhance production capacity [1] - The expansion aims to increase the production of inhalation aerosol products to better meet the treatment needs of patients with respiratory diseases such as asthma and COPD [1] Investment and Production Expansion - The Qingdao facility expansion will utilize energy-saving technologies to achieve near-zero carbon operations [1] - AstraZeneca's Wuxi facility has achieved 100% renewable energy usage and is recognized for implementing innovative clean heating solutions, receiving carbon neutrality certification [1] - The Taizhou facility has reduced carbon emissions by 97.5% compared to 2015 levels, with the Qingdao facility expected to achieve similar near-zero carbon operations upon completion [1] Innovative Drug Offerings - At the expo, AstraZeneca presented two newly approved oncology drugs in China: QianKede® (Capecitabine Tablets) and Dazhuoyou® (Darbepoetin Alfa Injection) [2] - The company also showcased innovative therapies for various new disease areas [2]